Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriasis Nail Clear all
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

NCT01807520
View directory record Official record
Conditions
Moderate to Severe Nail Psoriasis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

NCT03991936
View directory record Official record
Conditions
Nail Psoriasis, Nail Diseases
Interventions
Placebos, Triamcinolone Acetonide 2.5 mg/mL, Triamcinolone Acetonide 5.0 mg/mL, Triamcinolone Acetonide 7.5 mg/mL, Triamcinolone Acetonide 10 mg/mL
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 22, 2026, 6:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Psorcast Mobile Study

NCT05621369
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Interventions
Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo, Finger and Toe Photos, Digital Jar Open, 30 Second Walk, Psorcast mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617
View directory record Official record
Conditions
Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 22, 2026, 6:41 PM EDT
Terminated Phase 4 Interventional

Local Methotrexate Injections for the Treatment of Nail Psoriasis

NCT06578728
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

NCT04227288
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Enstilar Foam
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Not listed Phase 4 Interventional

Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

NCT05135312
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis, Psoriatic Nail
Interventions
Etanercept, OCT
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 22, 2026, 6:41 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973
View directory record Official record
Conditions
Nail Psoriasis
Interventions
P-3073 (calcipotriene 0.005%), Vehicle of P-3073
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions
Tildrakizumab, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Early Phase 1 Interventional

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

NCT05124080
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Deucravacitinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 6:41 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 4 Interventional

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

NCT04535999
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab Auto-Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 22, 2026, 6:41 PM EDT
Terminated Phase 4 Interventional Results available

Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles

NCT02181790
View directory record Official record
Conditions
Psoriasis, Skin or Nails
Interventions
Excimer laser, Acitretin
Device · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

308nm Excimer Laser for Treatment of Fingernail Psoriasis

NCT02168933
View directory record Official record
Conditions
Nail Psoriasis
Interventions
308 nm excimer laser, Sham laser
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Jul 22, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jul 22, 2026, 6:41 PM EDT